<DOC>
	<DOC>NCT02932410</DOC>
	<brief_summary>This is a prospective, multicenter, open-label, randomized, controlled, parallel group, group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and PK of macitentan in children.</brief_summary>
	<brief_title>A Study to Find Out Whether the Medicine Macitentan Works in Children With Pulmonary Arterial Hypertension (PAH)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1. Signed informed consent by the parent(s) or legally designated representative AND assent from developmentally capable children prior to initiation of any studymandated procedure. 2. Males or females between ≥ 2 years and &lt; 18 years of age. 3. Subjects with body weight ≥ 10 kg at randomization. 4. PAH diagnosis, confirmed by historical RHC (mPAP ≥ 25 mmHg, and PAWP ≤ 15 mmHg, and PVR &gt; 3 WU). 5. PAH belonging to the Nice 2013 Updated Classification Group 1 (including subjects with Down syndrome) and of following etiologies: iPAH hPAH PAH associated with CHD Drug or toxin induced PAH PAH associated with HIV PAHaCTD 6. WHO FC I to III. 7. Females of childbearing potential must have a negative pregnancy test at Screening and at Baseline, and must agree to undertake monthly pregnancy tests, and to use a reliable method of contraception (if sexually active) up to EOS. 1. Subjects with PAH due to portal hypertension, schistosomiasis, or with pulmonary venoocclusive disease and/or pulmonary capillary hemangiomatosis, and persistent pulmonary hypertension of the newborn. 2. Subjects receiving a combination of &gt; 2 PAHspecific treatments at randomization. 3. Treatment with i.v. or s.c. prostanoids within 4 weeks before randomization, unless given for vasoreactivity testing. 4. Hemoglobin or hematocrit &lt;75% of the lower limit of normal range 5. Serum AST and/or ALT &gt; 3 times the upper limit of normal range' 6. Pregnancy (including family planning) or breastfeeding. 7. Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>